ArticleScientific reports2026
Plasma acylcarnitine dysregulation associated with CPT1-mediated metabolism contributes to oral carcinogenesis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Growing evidence suggests that lipid metabolic reprogramming occurs in oral cancer (OC). We characterized circulating metabolic alterations associated with lipid metabolic reprogramming in OC. Semi-targeted and targeted plasma metabolomic profiling was performed in a discovery cohort (182 OC, 364 healthy controls [HC]) followed by independent external validation (52 OC, 52 HC). Machine learning approaches were used to identify plasma metabolites with strong discriminatory performance between patients with OC and healthy controls. Targeted validation confirmed consistent metabolic changes. Namely, three medium-chain acylcarnitines-decanoyl-, octanoyl-, and hexanoylcarnitine-were markedly downregulated in OC plasma, demonstrating consistent and reproducible discrimination during external validation (AUC = 0.941, 95% CI: 0.877-0.988). Pathway enrichment analysis further suggested altered β-oxidation and glycerophospholipid metabolism in OC. We also observed elevated carnitine palmitoyltransferase 1 (CPT1) expression in OC tissues and cells. Moreover, pharmacological inhibition of CPT1 suppressed OC cell growth and altered acylcarnitine profiles. These findings support an association between circulating acylcarnitine alterations and CPT1-related lipid metabolic reprogramming in OC. Furthermore, they provide biological context supporting the association between circulating metabolic alterations and CPT1-related lipid metabolic reprogramming in OC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.